Abstract:Introduction: Previous study showed the standard dose of immunosuppressants enteric-coated mycophenolate sodium (EC-MPS) might result in unsatisfactory control rate of effective blood concentration and improvable acute rejection rate. This prospective cohort study was designed to evaluate the efficacy and safety of an intensified dosing regimen of EC-MPS in de novo kidney transplant recipients in China. Methods: This prospective cohort study enrolled patients underwent de novo renal transplantation from 2015.6 to 2018.9. Participants were divided into the intensified-dose (week 1: 2160 mg/day; week 2: 1440 mg/day; followed by 720-1080 mg/day) and standard-dose (week 1: 1440 mg/day; week 2: 1080 mg/day; followed by 720-1080 mg/day) groups. Sub-group were analyzed based on mycophenolic acid (MPA)-area under the concentration (AUC): achieved group (defined as patients whose MPA AUC is equal or beyond 40 mg.h/L within Day 7) and under exposure group (defined as patients whose MPA AUC is below 40 mg.h/L within Day 7). The primary endpoints were 12-month-biopsy-proven acute rejection (BPAR), graft and patient survival rates. safety were also assessed. The study was followed up 3 years. Results: A total of 128 patients were included, with 65 and 63 patients in the intensified-dose group and standard-dose group, respectively. The 12-month-BPAR incidence was numerically lower in the intensified-dose group than standard-dose group (4.6% vs. 9.5%, p=0.320). The rate of patients achieving target mycophenolic acid (MPA)-area under the concentration (AUC) was significantly higher in the intensified-dose group (87.5% vs. 69.8%, p=0.015) (Table 1) than standard-dose group, and patients achieving target MPA-AUC had a significantly lower 3-month-BPAR incidence (1.0% vs. 11.1%, p=0.03) (Table 2). patient and graft survival rates at 36 months between the intensified-dose and standard-dose groups was 98.5% vs. 100.0% and 98.5% vs. 100.0%, respectively. The 36-month- de novo donor-specific antibody (dnDSA) positive incidence rates was numerically lower in the intensified-dose group than standard-dose group (1.5% vs. 6.3%, p=0.204). In addition, delayed graft function, treatment failure, serum creatine levels, eGFRs and infection incidence had no significant differences between the two groups (all p>0.05) (Figure 1). The incidence rates of infection were similar in both groups (29.2% vs. 33.3%, p=0.617). No additional safety concerns related to intensified dosing of EC-MPS. Conclusion: Intensified dosing of EC-MPS results in a numerically lower incidence of 12-month-BPAR and lower positive incidence of dnDSA with 36 months follow up. Intensified dosing could help achieve target therapeutic blood concentration of EC-MPS, that showed significantly lower BPAR and no more infection incidence increased and might further improve long-term prognosis in Chinese de novo kidney transplantation recipients.

Effects of 16,16-Dimethyl Prostaglandin E_2 on Cyclosporine Nephrotoxicity in Rats

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Effects of rapamycin on chronic nephrotoxicity induced by cyclosporine A in rats

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

The effects of diltiaze in renal transplantation patients treated with cyclosporine A

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Differential Expression of Plasma Proteins in Cyclosporine A-Induced Rat Acute Nephrotoxicity

Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax

Amelioration of Cyclosporine A-Induced Acute Nephrotoxicity by Cordyceps cicadae Mycelia via Mg+2 Reabsorption and the Inhibition of GRP78-IRE1-CHOP Pathway: In Vivo and In Vitro

Experimental Study on Effect of Cordyceps Sinensis on Renal Protection, Urinary Enzymes and Nephrotoxicity of Cyclosporine a in Rats

Cordyceps Sinensis Extractant Protect Against Cyclosporine Induced Injury of Tubular Epithelium Cell

Chronic injury of human renal microvessels with low-dose cyclosporine therapy

Effects of glycerides on the intestinal absorption of cyclosporine a using the in-situ mesenteric vein cannulated rat model

Protective Effect of Low Dose Cyclosporine-a on Ischemic-Reperfusional Kidney

Pyrvinium pamoate ameliorates cyclosporin A- induced hepatotoxicity via the modulation of Wnt/β-catenin signaling and upregulation of PPAR-γ

Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats

Effects of Prednisolone on the Physiological Factors Regulating Cyclosporin A Blood Distribution in Renal Transplant Patients.

Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells